BRAF and colorectal carcinoma: ,23,27 Our analyses suggest that in unselected early-stage CRC AIMMeR used at a sensitivity of 0.98 could classify more than three-quarters of cases as MMRp, while its near-perfect ability to identify combined MLH1-PMS2 loss could potentially action reflex BRAF mutation or MLH1 promoter methylation testing to differentiate germline and sporadic causes30,31 without delay caused by human review.